She Wong Hoi, Cheung Tan To
Division of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Department of Surgery, the University of Hong Kong, Queen Mary Hospital, Hong Kong.
Transl Gastroenterol Hepatol. 2016 Apr 14;1:34. doi: 10.21037/tgh.2016.03.04. eCollection 2016.
Hepatocellular carcinoma (HCC) is a common primary malignancy worldwide especially in the patients with the background of chronic liver disease. Liver transplantation (LT) is the only curative treatment effective for both malignancy as well as the cirrhosis and portal hypertension. Unfortunately, living donor is not always possible and the deceased graft is scarce. Neoadjuvant therapies, therefore, have been developed as a downstaging treatment to try to downstage the tumor within the transplant criteria, or as a bridging therapy to control the tumor growth in patients while waiting in the transplant list. This paper reviewed the common modalities used as bridging and downstaging therapies for patients suffering from HCC before undergoing LT.
肝细胞癌（HCC）是全球常见的原发性恶性肿瘤，尤其是在患有慢性肝病的患者中。肝移植（LT）是唯一对恶性肿瘤以及肝硬化和门静脉高压均有效的治愈性治疗方法。不幸的是，活体供体并非总是可行，而尸体供肝也很稀缺。因此，新辅助治疗已被开发出来，作为一种降期治疗，试图使肿瘤降至移植标准以内，或者作为一种桥接治疗，在患者等待移植名单期间控制肿瘤生长。本文综述了在LT前用于HCC患者的桥接和降期治疗的常见方式。
